Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Leuk Lymphoma
; 14(3-4): 257-62, 1994 Jul.
Article
em En
| MEDLINE
| ID: mdl-7950914
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Interleucina-2
/
Toxina Diftérica
/
Transtornos Linfoproliferativos
/
Antineoplásicos
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1994
Tipo de documento:
Article